636 related articles for article (PubMed ID: 9062500)
21. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
[TBL] [Abstract][Full Text] [Related]
22. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
24. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
25. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
26. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.
De Luis DA; Becerra A; Lahera M; Botella JI; Valero ; Varela C
J Endocrinol Invest; 2000; 23(7):428-34. PubMed ID: 11005266
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
[TBL] [Abstract][Full Text] [Related]
28. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
29. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
30. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Muratori M; Arosio M; Gambino G; Romano C; Biella O; Faglia G
J Endocrinol Invest; 1997 Oct; 20(9):537-46. PubMed ID: 9413808
[TBL] [Abstract][Full Text] [Related]
31. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
32. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
33. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
34. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
36. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
[TBL] [Abstract][Full Text] [Related]
37. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
38. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
39. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
40. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
